Robert Bowser, Ph.D. – Founder and President. Dr. Bowser developed the protein signatures for both the ALS diagnostic test and the ALS prognostic test. Dr. Bowser has published over 180 articles in peer-reviewed journals and has been the recipient of a large number of federal grants for his research. Dr. Bowser is also a Professor of Neurology and Neurobiology at the Barrow Neurological Institute and St. Joseph’s Hospital and Medical Center in Phoenix, Arizona. He is also Director of the Gregory W. Fulton ALS Research Center at the Barrow Neurological Institute. Dr. Bowser was co-Founder of Knopp Biosciences, a drug development company located in Pittsburgh, PA, and has consulted for a number of pharmaceutical and biotechnology companies. Dr. Bowser earned his B.S. in Biological Sciences from Carnegie Mellon University and Ph.D. in Cell Biology from Yale University.
Andreas Jeromin, Ph.D. – Chief Scientific Officer for assay development, business development, and regulatory guidance. Dr. Jeromin was Director of Business Development and Assay Development for Banyan Biomarkers for the past three years and Chief Scientific offer of NextGen Sciences, Inc. Dr. Jeromin participates on multiple national and international committees for the validation of biomarkers for Alzheimer’s disease and Parkinson’s disease and has co-authored more than 150 publications and is one of the international leaders in CNS biomarkers.
Michael Hull, MBA – Chief Financial Officer – Mr. Hull has extensive experience in financial, operational support and commercializing discoveries for start-ups.
He co-founded InVent Life Sciences, a commercialization company focused on life science discoveries and worked with numerous research institutions and small businesses on obtaining small business grants for further validation studies on the path to commercialization. He has vast experience in building operations to scale for technology companies and working with research teams to commercialize their discoveries.
Gerry Shaw, Ph.D., – Co-Founder and Scientific Advisor. Dr. Shaw is Professor of Neurosciences at the University of Florida and has performed research on the cytoskeleton for the past 25 years. Dr. Shaw is also Founder and President of EnCor Biotechnology Inc., a company that specializes in the generation of antibodies. EnCor will provide Iron Horse antibodies for use in all products, with exclusive license for use of EnCor antibodies in clinical diagnostic assays.
Jiyan An, Lab Manager – Ms. An has over 20 years of lab work experience including the University of Pittsburgh Proteomics Core Lab and Pathology Department, PPD and Sequel Genetics. She is also a laboratory technician at the Barrow Neurological Institute.